Podium to Practice: ESMO® 2025 – GU: PSMAddition
OR
Explore more from your favourite experts – click their name to access their entire library of content.
Speakers
Studies / Trials Discussed
LBA6 – Phase 3 trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)
Studies/trials discussed:
LBA6 – Phase 3 trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.